

Table S6. YM155 concentrations that reduce the viability of neuroblastoma cell lines by 50% (IC₅₀, mean ± S.D., n = 3) in the absence or presence of zosuquidar (1.25µM) as indicated by MTT assay or CellTiterGlo after 120h of incubation.

Cell line	YM155 IC ₅₀ (nM)	+ Zosuquidar ¹
IMR-5 (MTT)	7.18 ± 1.04	10.64 ± 2.80
IMR-5 (CellTiterGlo)	6.27 ± 1.56	19.99 ± 5.97
IMR-5'DOCE ²⁰ (MTT)	21,549 ± 638	13.63 ± 5.54
IMR-5'DOCE ²⁰ (CellTiterGlo)	32,946 ± 4360	14.82 ± 4.66
IMR-32 (MTT)	1.40 ± 0.35	1.80 ± 0.23
IMR-32 (CellTiterGlo)	1.22 ± 0.21	1.91 ± 1.16
IMR-32'DOX ²⁰ (MTT)	35.53 ± 2.23	0.94 ± 0.08
IMR-32'DOX ²⁰ (CellTiterGlo)	29.20 ± 3.56	0.86 ± 0.06

¹ The effects of zosuquidar alone are provided in Table S5.